Next Article in Journal
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
Next Article in Special Issue
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Previous Article in Journal
Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy
Previous Article in Special Issue
Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma
 
 
Article

Article Versions Notes

Cancers 2023, 15(8), 2373; https://doi.org/10.3390/cancers15082373
Action Date Notes Link
article xml file uploaded 19 April 2023 12:07 CEST Original file -
article xml uploaded. 19 April 2023 12:07 CEST Update -
article pdf uploaded. 19 April 2023 12:07 CEST Version of Record https://www.mdpi.com/2072-6694/15/8/2373/pdf-vor
article supplementary file uploaded. 19 April 2023 12:07 CEST - https://www.mdpi.com/2072-6694/15/8/2373#supplementary
article html file updated 19 April 2023 12:08 CEST Original file -
article xml file uploaded 26 April 2023 06:33 CEST Update -
article xml uploaded. 26 April 2023 06:33 CEST Update https://www.mdpi.com/2072-6694/15/8/2373/xml
article pdf uploaded. 26 April 2023 06:33 CEST Updated version of record https://www.mdpi.com/2072-6694/15/8/2373/pdf
article html file updated 26 April 2023 06:35 CEST Update https://www.mdpi.com/2072-6694/15/8/2373/html
Back to TopTop